P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT - PACE-CME

PY inhibitor monotherapy for months after month of DAPT compared to traditional month DAPT

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension
Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension
ESC 2018
Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension
- Dr. Ajay Gupta
Shared decision-making with lifetime risk model
Shared decision-making with lifetime risk model
ESC 2018
Shared decision-making with lifetime risk model
- Dr. Jannick Dorresteijn
The predictive role of biomarkers in CV risk assessment
The predictive role of biomarkers in CV risk assessment
ESC 2018
The predictive role of biomarkers in CV risk assessment
- Nina Paynter, PhD
Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients
Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients
ESC 2018
Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients
- Prof. Thomas Engstrom